Project Details
Description
Project Summary/Abstract
Tumors have distinctive metabolism. These distinguishing metabolic features enable both cancer diagnosis and
therapy. Due to fast glucose metabolism, tumors light up by fluorodeoxyglucose PET imaging. Due to enhanced
nucleotide synthesis, they are susceptible to antifolates, which are first-line therapies for leukemia (methotrexate)
and lung cancer (pemetrexed). New facets of tumor metabolism continue to be discovered. Previously, co-PIs
White and Rabinowitz contributed to the identification of autophagy and macropinocytosis as non-canonical
means of cancer cell nutrient acquisition. Recently, they identified thrifty energy metabolism in tumors: by
shedding normal tissue functions, tumors can grow and divide despite making less energy than most normal
tissues. While valuable, up to now studies measuring tumor metabolic activity (e.g. with isotope tracing and mass
spectrometry) have mainly studied the tumor as a whole. In the current era of immunotherapy, the insufficiency
of this approach is painfully clear. Whole tumor measurements confound the metabolism of cancer cells and
cancer-fighting immune cells. To resolve metabolism in tumors with cell type specificity, new methods are
needed. Here we will develop and deploy such methods. The resulting knowledge will provide the basis for
manipulating metabolism more effectively to help fight cancer. Aim 1 will determine, in state-of-the-art mouse
modes, in vivo central metabolic fluxes (glycolysis, TCA) across different tumor cell types and during active
response to immunotherapy. Aim 2 will measure how different tumor cell types obtain nucleotides. Nucleic acid
synthesis is a clinically proven cancer vulnerability but at the same time, nucleotide synthesis inhibitors can also
impair immune cells. We will assess nucleotide synthesis and scavenging, and how it changes in response to
anti-folates. Defining the dynamics of nucleotide metabolism in vivo with cellular resolution will inform the
metabolic relationship between tumor and immune cells in the tumor microenvironment. Aim 3 will explore the
interplay between autophagy, metabolism, and antitumor immunity. Autophagy supports tumor cell metabolism,
and host autophagy supplies nutrients to tumors and dampens antitumor immunity. We will use mouse genetics,
nutrient supplementation, single cell transcriptomics, and in vivo isotope-tracing of host and tumor metabolism
to define underlying mechanisms. The net impact of these efforts will be (i) broadly useful methods for tracking
metabolism in action across cell types, (ii) fundamental knowledge of the metabolic feedstocks and pathways
used by different tumor cells, and (iii) next-generation metabolic strategies for treating cancer.
Status | Active |
---|---|
Effective start/end date | 8/7/12 → 5/31/26 |
Funding
- National Cancer Institute: $440,730.00
- National Cancer Institute: $480,941.00
- National Cancer Institute: $466,524.00
- National Cancer Institute: $476,594.00
- National Cancer Institute: $444,948.00
- National Cancer Institute: $428,527.00
- National Cancer Institute: $458,236.00
- National Cancer Institute: $434,619.00
- National Cancer Institute: $501,299.00
- National Cancer Institute: $451,234.00
Fingerprint
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.